News for Citius Pharmaceuticals Stock (CTXR)

Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19

PRNewsWire • 07/22/20

Citius Pharmaceuticals to Present at the MoneyShow Accredited Investor Virtual Event

PRNewsWire • 07/20/20

Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D.

PRNewsWire • 07/14/20

Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

PRNewsWire • 07/13/20

Citius Pharmaceuticals (CTXR) Jumps: Stock Rises 5.1%

Zacks Investment Research • 06/30/20

Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides

PRNewsWire • 06/29/20

Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19

PRNewsWire • 06/26/20

Citius Pharmaceuticals to Deliver Virtual Presentation at the Life Sciences Investor Forum

PRNewsWire • 06/22/20

Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok® Therapy

PRNewsWire • 06/02/20

Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok®

PRNewsWire • 05/26/20

Citius Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

PRNewsWire • 05/18/20

Why Citius Pharmaceuticals Is Trading Higher Today

Benzinga • 04/01/20